Navigation Links
Frost & Sullivan Recognizes CRi for Innovations Leading to Personalized Medicine
Date:4/13/2009

SAN FRANCISCO, April 13 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) was presented with Frost & Sullivan's United States Optical Imaging Technologies in Drug Discovery Product Line Strategy Award at the 2009 Excellence in Medical Technologies & Life Sciences award banquet.

The Award recognizes CRi's product development strategy for the in-vitro and in-vivo imaging markets, achieved by creating innovative solutions that address a wide range of unmet needs in life sciences applications. The company's Nuance(TM) and Maestro(TM) multispectral solutions enable researchers and clinicians to quantitatively analyze multiple molecular markers in single cells, in tissues, and in whole organisms, aiding in the understanding the behavior of signaling pathways. Such knowledge is essential for guiding drug development and clinical trials designs.

"By facilitating the analysis of complex biological systems, our solutions are helping our customers build the foundation for personalized medicine," said George Abe, President and CEO of CRi. "It is very rewarding that the technical and strategic approach being taken by the team at CRi is being further recognized with such an award."

CRi recently introduced inForm(TM), an advanced image analysis program that employs machine learning technology to solve challenging image analysis problems. inForm combines a fast, easy to use learn-by-example image segmentation engine with powerful data analysis tools. Unlike conventional systems, the combination of Nuance and inForm can automatically identify and quantify relevant molecular expression patterns and signaling pathway data from clinically relevant cells and tissue regions.

CRi's image analysis software products automate, standardize, and simplify the complex and challenging tasks associated with measuring parameters and signals from associated molecular markers. Reliable data that reflect the distribution of specific molecular markers are essential for obtaining valuable insights into disease mechanisms and can help deliver information that will be required for true personalized medicine to become a reality.

Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.

With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility.

For more information, please visit: http://www.cri-inc.com

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.


'/>"/>
SOURCE Cambridge Research and Instrumentation, Inc. (CRi)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan Honours LyondellBasell With Customer Value Enhancement Award
2. Rise in Sleeping Disorders Triggers High Demand for Sleep Service Facilities in Europe, Notes Frost & Sullivan
3. BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivans Product Innovation of the Year Award
4. Kenyan Pharmaceutical Industry Can Expect Significant Growth Despite Global Conditions, Finds Frost & Sullivan
5. Tough Recessionary Times, but Frost & Sullivan Believes Its Not All Gloomy for African Healthcare Markets
6. Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia
7. Frost & Sullivan: End-to-End Integration of HD Devices in the Operating Room Ushers in a New Era in Disruptive Technology
8. Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan
9. Frost & Sullivan Accolade for Ferring Pharmaceuticals
10. Leveraging the Third Amendment Ruling the Risk Management Process: Frost & Sullivans Assessment of Regulations for Medical Imaging Equipment in Europe
11. Frost & Sullivan Honours Outstanding Achievements in Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 ... ... Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex ... into a definitive agreement to purchase Unitrans International Corporation, a division of ...
(Date:8/18/2017)... New York, NY (PRWEB) , ... August 18, ... ... summer’s edition of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and ... today’s resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... protection services and financial consultations to communities throughout the greater DC region, is ... with the goal of rescuing local animals and training them to be companions ...
(Date:8/18/2017)... FL (PRWEB) , ... August 18, 2017 , ... ... protection and financial planning assistance that serves communities throughout southern Florida, is working ... to provide scholarship assets to children from low income families. , The Take ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... TEL AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. ... and immunology, today reports its financial results for the ... and achievements during the second quarter 2017 and to ... on multiple clinical development programs for the Company,s lead ... Phase 3 pivotal study with BL-8040 as novel stem ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
Breaking Medicine Technology: